{"nctId":"NCT03480022","briefTitle":"Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS","startDateStruct":{"date":"2018-09-26","type":"ACTUAL"},"conditions":["Pre Diabetes","Polycystic Ovary Syndrome","Obesity Android"],"count":88,"armGroups":[{"label":"Liraglutide Pen Injector (Saxenda)","type":"EXPERIMENTAL","interventionNames":["Drug: Liraglutide Pen Injector [Saxenda]"]},{"label":"Placebo liraglutide pen injector","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Liraglutide Pen Injector"]}],"interventions":[{"name":"Liraglutide Pen Injector [Saxenda]","otherNames":["Liraglutide 3mg","Saxenda"]},{"name":"Placebo Liraglutide Pen Injector","otherNames":["Placebo Saxenda","Placebo liraglutide 3 mg"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female gender\n* 18-45 years of age\n* BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with one or more obesity-associated co-morbid conditions (e.g. hypertension, and dyslipidemia)\n* PCOS- NIH criteria hyperandrogenism and irregular menstrual cyclicity\n* Non-diabetic as determined by a 75 gram oral glucose tolerance test (OGTT) and hemoglobin A1C. Non-diabetic is inclusive of women with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT). Participants with diabetes will be excluded\n* Willing to use effective contraception consistently during therapy which is defined as:\n\n  * an intrauterine device, tubal sterilization, or male partner vasectomy, or\n  * combination of two barrier methods with one being male condom.\n* Written consent for participation in the study\n\nExclusion Criteria:\n\n* Presence of significant systemic disease, cerebrovascular disease, clinically significant cardiac abnormalities or heart problems including congestive heart failure, unstable angina or acute myocardial infarction, current infectious liver disease, acute stroke or transient ischemic attacks, history of pancreatitis, or diabetes mellitus (Type 1 or 2)\n* Any hepatic diseases in the past (infectious liver disease, viral hepatitis, toxic hepatic damage, jaundice of unknown etiology) or severe hepatic insufficiency and/or significant abnormal liver function tests defined as aspartate aminotransferase (AST) \\>3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \\>3x ULN\n* Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women, or eGFR \\<60 mL/min/1.73 m2) or history of unstable or rapidly progressing renal disease or end stage renal disease.\n* Uncontrolled thyroid disease (documented normal TSH), Cushing's syndrome, congenital adrenal hyperplasia or clinically significant elevations in prolactin levels. The clinical significance of prolactin levels will be determined by the treating physician\n* Significantly elevated triglyceride levels (fasting triglyceride \\> 400 mg %)\n* Untreated or poorly controlled hypertension (sitting blood pressure \\> 160/95 mm Hg)\n* Use of hormonal medications, the use of medications that cause clinically significant weight gain or loss (prescription or OTC) and medications known to exacerbate glucose tolerance (such as isotretinoin, hormonal contraceptives, GnRH analogues, glucocorticoids, anabolic steroids, C-19 progestins) including herbal medicines for at least 8 weeks. Use of anti-androgens that act peripherally to reduce hirsutism such as 5-alpha reductase inhibitors (finasteride, spironolactone, flutamide) for at least 4 weeks\n* Prior history of a malignant disease requiring chemotherapy\n* Family or personal history of familial medullary thyroid carcinoma or multiple endocrine neoplasia type 2\n* Known hypersensitivity or contraindications to use GLP1 receptor agonists\n* Use of metformin, thiazolidinediones, GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium/glucose co-transporter 2 (SGLT2) inhibitors or weight loss medications (prescription or OTC) stopped for at least 4 weeks\n* Prior use of medication to treat diabetes except gestational diabetes\n* Eating disorders (anorexia, bulimia) or gastrointestinal disorders\n* Suspected pregnancy (documented negative serum pregnancy test), desiring pregnancy in next 15 months, breastfeeding, or known pregnancy in last three months\n* Active or prior history of substance abuse (smoke or tobacco use within past 6 months) or significant intake of alcohol\n* Previous bariatric surgery or device intervention for obesity\n* Patient not willing to use barrier contraception during study period (unless sterilized or have an IUD)\n* History of major depressive or other severe psychiatric disorders\n* Inability or refusal to comply with protocol\n* Currently participating or having participated in an experimental drug study in previous three months","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"genderDescription":"Patients must be female to have the disorder being studied since it involved the female reproductive system","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Body Weight (BW)","description":"Treatment impact on change in body weight after 32 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.7","spread":"2.9"},{"groupId":"OG001","value":"117.9","spread":"5"}]}]}]},{"type":"PRIMARY","title":"Free Androgen Index (FAI)","description":"Drug treatment effect on free androgen levels as calculated as FAI= total testosterone (T) concentrations divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome (more androgenic).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.98","spread":"0.6"},{"groupId":"OG001","value":"6.4","spread":".75"}]}]}]},{"type":"SECONDARY","title":"Body Mass Index (BMI)","description":"Treatment effect in reducing body mass","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":"1.1"},{"groupId":"OG001","value":"43.4","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Change in Percent Body Weight","description":"Treatment effect on reducing body weight expressed as percent body weight loss from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"0.75"},{"groupId":"OG001","value":"1.4","spread":"1.09"}]}]}]},{"type":"SECONDARY","title":"5% Weight Loss From Baseline","description":"Frequency of patients achieving 5% weight loss from baseline with treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"10% Body Weight Loss From Baseline","description":"Frequency of patients with at least 10% reduction in body weight from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Abdominal Adiposity (Waist Circumference [WC]","description":"Treatment effect on loss of WC (abdominal adiposity) with drug treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.9","spread":"2.0"},{"groupId":"OG001","value":"109.9","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Waist-to-Hip Ratio","description":"Change in central adiposity with treatment as measured by WHR. A reduction in ratio indicates a decrease in truncal fat.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.009"},{"groupId":"OG001","value":"0.85","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Waist-to Height Ratio [WHtR])","description":"Treatment effect on loss of central adiposity as determined by WHt ratio. The lower the ratio indicates less abdominal adiposity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":"0.014"},{"groupId":"OG001","value":"0.67","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Total Fat Mass Evaluated by DEXA","description":"Treatment effect on reduction of fat mass (kg)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":"2.1"},{"groupId":"OG001","value":"56.8","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Total Body Fat (%) by DXA","description":"Treatment effect on reduction of percent body fat by DXA","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":"0.9"},{"groupId":"OG001","value":"47.9","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Android-Gynoid Ratio (AGR) by DXA","description":"Treatment impact on AGR, measure of central adiposity, as determined by DXA. A lower AGR indicates a reduction in central adiposity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"0.01"},{"groupId":"OG001","value":"1.08","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Trunk/Leg Fat Ratio (TLR) by DXA","description":"Treatment impact on TLR after 32 weeks. A reduction in TLR indicates a loss of central fat.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"0.03"},{"groupId":"OG001","value":"1.07","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Menstrual Cycle Frequency","description":"Drug treatment impact on normalization of cycle frequency (cycle every 28-30 days). All cycle data is expressed as number of menses annualized to one year.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.65","spread":"0.4"},{"groupId":"OG001","value":"4.8","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Total Testosterone Concentrations (T)","description":"Drug treatment effect on total testosterone concentrations","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.4","spread":"3.0"},{"groupId":"OG001","value":"46.8","spread":"4.1"}]}]}]},{"type":"SECONDARY","title":"Adrenal Dehydroepiandrosterone Sulfate (DHEAS)","description":"Treatment efficacy in reducing adrenal hyperandrogenism","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"177.1","spread":"14.2"},{"groupId":"OG001","value":"171.3","spread":"16.8"}]}]}]},{"type":"SECONDARY","title":"Fasting Blood Glucose (FG)","description":"Treatment effect on fasting glucose prior to an oral glucose tolerance test (OGTT)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":"1.3"},{"groupId":"OG001","value":"94.3","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"OGTT Mean Blood Glucose (MBG)","description":"Treatment effect on MBG measured during the oral glucose tolerance test. A decrease in MBG shows improvement in glycemia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109.4","spread":"2.9"},{"groupId":"OG001","value":"125.5","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"Fasting Insulin Sensitivity (HOMA-IR)","description":"Treatment effect on the HOMA-IR which is an insulin resistance measured derived from fasting blood glucose and insulin . The higher the number the more insulin resistant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"0.6"},{"groupId":"OG001","value":"5.2","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Matsuda Insulin Sensitivity Index Derived From the OGTT (SI OGTT)","description":"The SI OGTT is a measure of peripheral insulin sensitivity derived from the insulin and glucoses measured during an OGTT. A increase in SI OGTTindicates greater insulin sensitivity","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"0.43"},{"groupId":"OG001","value":"3.0","spread":"0.48"}]}]}]},{"type":"SECONDARY","title":"Corrected First Phase Insulin Secretion (IGI/HOMA-IR)","description":"Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"0.18"},{"groupId":"OG001","value":"0.8","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Insulin Secretion- Insulin Sensitivity Index (Oral Disposition Index-IS-SI)","description":"Treatment effect on an estimation of Beta cell compensatory function, the IS-SI is derived by applying the concept of the disposition index to measurements obtained during the 2 hour OGTT and calculated as the index of insulin secretion factored by insulin sensitivity. A higher score shows improved pancreatic beta cell function relative to insulin sensitivity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"532","spread":"91"},{"groupId":"OG001","value":"416","spread":"69.7"}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol Levels","description":"Treatment impact on improving total cholesterol levels","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":"5.3"},{"groupId":"OG001","value":"178","spread":"8.8"}]}]}]},{"type":"SECONDARY","title":"High Density Lipoprotein Cholesterol (HDL-C)","description":"Impact of treatment on HDL levels after 32 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":"1.8"},{"groupId":"OG001","value":"42","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Triglyceride Levels (TRG)","description":"Drug effect of TRG levels after treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":"7.7"},{"groupId":"OG001","value":"114","spread":"11"}]}]}]},{"type":"SECONDARY","title":"Triglyceride to HDL-Cholesterol Ratio (TRG/HDL-C)","description":"Treatment impact on TRG/HDL-C ratio which is a simple measure to estimate insulin action. A decrease in ratio indicates improvement in insulin sensitivity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.26"},{"groupId":"OG001","value":"3.0","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Triglyceride and Glucose Index (TyG)","description":"Treatment impact on the TyG index which estimates insulin resistance. A reduction in TyG indicates an improvement in insulin action.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.39","spread":"0.07"},{"groupId":"OG001","value":"8.5","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Systolic Blood Pressure","description":"Treatment impact on systolic blood pressure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116.8","spread":"2.7"},{"groupId":"OG001","value":"123.3","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Diastolic Blood Pressure (BP)","description":"Treatment impact on reducing diastolic blood pressure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":"1.6"},{"groupId":"OG001","value":"78.1","spread":"1.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":["Nausea","Vomiting","Diarrhea","Constipation","prolonged menstrual bleeding"]}}}